NEWS
![](https://oslocancercluster.no/wp-content/uploads/2021/01/Ingvild-Hagen_web2-260x185.jpg)
First pharma company joins IMPRESS-Norway
Roche contributes eight cancer medicines to IMPRESS-Norway.
![Eivind Lysheim](https://oslocancercluster.no/wp-content/uploads/2020/08/IMG_20200807_105157_web-260x185.jpg)
From pupil to full-time employee
Our school collaboration project has opened unexpected doors for Eivind.
![illustrasjon av handlingsplan for kliniske studier](https://oslocancercluster.no/wp-content/uploads/2021/01/handlingsplan_for_kliniske_studier1_web-260x185.jpg)
New political paper: Action Plan for Clinical Studies
Norwegian government to double the number of clinical studies.
![Dr Deborah Owen, Partner, Dehns. Photo: Dehns](https://oslocancercluster.no/wp-content/uploads/2021/01/Debbie-Owen-260x185.jpg)
Dehns acquires Norwegian office
Dehns acquires Norwegian Intellectual Property consultancy Leogriff.
![Carlos de Sousa, CEO of Ultimovacs](https://oslocancercluster.no/wp-content/uploads/2020/12/DSC_2859_web-260x185.jpg)
New clinical study in ovarian cancer
Ultimovacs has announced a new clinical study targeted at patients with ovarian cancer.
![](https://oslocancercluster.no/wp-content/uploads/2020/12/Jutta_Heix_ProjectManager_CONNECT-260x185.jpg)
Landmark public-private agreement for precision cancer medicine
CONNECT is a completely new public-private collaboration in cancer precision medicine.
![](https://oslocancercluster.no/wp-content/uploads/2020/12/jude-beck-0V_wq6o0a98-unsplash_web-260x185.jpg)
Oslo Cancer Cluster’s highlights 2020
Read a selection of our news from 2020.
![](https://oslocancercluster.no/wp-content/uploads/2020/12/OCC_memberwheel_oct2020-260x185.jpg)
Top news 2020 from Oslo Cancer Cluster's members
Read the top news from 2020 from a few of our members.
![](https://oslocancercluster.no/wp-content/uploads/2020/12/OSoug-3_web-260x185.jpg)
Positive results from Targovax’s skin cancer study
Update from Targovax on melanoma study shows responses in 7 of 20 patients.